Abstract. The aim of this study was to evaluate the effect of dose-dense adjuvant chemotherapy regimens with pegfilgrastim support on the phenotype of peripheral blood leukocytes in breast cancer patients. We evaluated the leukocyte phenotype of 14 patients aged 46-67 years undergoing 4 courses of chemotherapy with either epirubucin/ cyclophosphamide (n=7) or 5-fluorouracil/epirubucin/ cyclophosphamide (n=7) followed by 4 courses of taxol supported by peg-filgrastim (6 mg) administered 72 h after each chemotherapy course. The overall leukocyte number significantly increased from the first treatment course, while total lymphocytes tended to decrease with a negative peak following the 6th course (p=0.03). B (CD19 + , CD20 + ) and early B lymphocyte subsets (CD20 + /CD38 + ) significantly decreased during treatment (p<0.05), while T lymphocyte subsets did not show significant changes, except a decrease in T helper (CD4 + ) cells. Immature T lymphocytes (CD4 + / CD8 + subset), dendritic cells (CD11c + ) and NK cells (CD56 + ) increased with respect to the baseline. Our results suggest that dose-dense chemotherapy programs with the support of pegfilgrastim did not significantly impair the immune system of breast cancer patients and allowed for a rapid restoration of most immune competent cells. These observations may have important clinical implications with a view to vaccination or other immunotherapeutic approaches to solid tumours.
Introduction
Very complex interactions occur between tumours and the immune system. The immune system plays an important role in the control of tumour growth, and its direct anti-tumour activity seems to have a critical impact on the prognosis of cancer patients. It has been reported that cell-mediated immunity to tumour-associated antigen may predict survival better than tumour stage, grade and lymph node status (1) . However, chemotherapy (CT) is considered to be a major cause of immune deficiency in cancer patients. T-cell deficiency has been reported following cytotoxic antineoplastic therapy leading to frequent opportunistic infections (2) . The immunosuppressive effects of antineoplastic agents such as alkylating agents, fludarabine, melphalan, thiotepa and cyclophosphamide are well established. Little information is available concerning the actual impact on the immune system of other widely used antineoplastic drugs, such as platinum derivatives, anthracyclines, etoposide and 5-fluorouracil.
Dose-dense CT regimens have shown very promising results in the adjuvant treatment of primary breast cancer (3), with less toxicity as compared to dose-escalation regimens. Haematological support with granulocyte-colony stimulating factor (G-CSF), either natural or pegylated, was demonstrated to reduce the duration and severity of CT-induced neutropenia, and thus infectious complications and hospitalizations. G-CSF also has an impact on the immune system; it has been shown to influence cytokine production and to modify T and B lymphocyte subsets (4) (5) (6) .
Dendritic cells are a subpopulation of leukocytes, identifiable in fresh blood only through cytofluorography. Their potential applications in the immunotherapeutic management of cancer have been investigated (7) .
We previously investigated the in vivo effect of topotecan on the peripheral blood leukocyte (PBL) phenotype and found that the drug did not negatively influence the lymphocyte subsets of either CT-naïve or pre-treated ovarian cancer patients (8) . The aim of this study was to evaluate the effect of dose-dense adjuvant CT regimens with G-CSF support on the phenotype of PBLs, including dendritic cells, in patients with breast cancer. Table I . Twenty healthy subjects, aged 18-60 years, were used as controls.
Patients and methods

Patients
Flow cytometry. The PBL phenotype was analysed by flow cytometry before the start of treatment and immediately before each CT course planned at a 14-day interval. A 3-ml sample of whole blood was obtained by venupuncture from all patients and controls, and EDTA was added. Each sample (100 μl) was incubated with the respective antibody solution for 10 min at room temperature in the dark. Erythrocyte lysis and leukocyte fixation were obtained using the Immunoprep Reagent System (Beckam Coulter, USA). For analysis of the PBL phenotype, the following monoclonal antibodies or combinations of monoclonal antibodies were used: fluorescein isothiocyanateconjugated (FITC) anti-CD2, phycoerythrin-conjugated (PE) anti-CD3, FITC anti-CD4, PE anti-CD4, FITC anti-CD8, FITC anti-CD10, PE anti CD-16, PE anti-CD19, FITC anti-CD20, FITC anti-CD23, PE anti-CD25, PE anti-CD38, PE anti-CD45RA, FITC anti-CD45RO, PE anti-CD56 and FITC anti-HLA-DR. Flow cytometric analysis was performed using Epics XL flow cytometer (Beckham Coulter) equipped with an argon ion laser working at 488 nm. The lymphocyte subsets were identified by forward and side scatter analyses. A total of 3000 events were analysed. Circulating dendritic cells (DCs) were evaluated on peripheral blood mononuclear cells (PBMCs) separated from 8 ml of whole blood by density gradient at 1077 g/l (Ficoll-Paque, Pharmacia-Amersham, Sweden). DCs were identified as Table I . Patient characteristics. Figure 1 . B and early B lymphocyte subsets from normal donors and breast cancer patients at baseline after 7 courses of chemotherapy and one month after the end of treatment. CD19 + : t1-t7 and t8 vs t0, p<0.05; CD20 + : t1-t7 and t8 vs t0, p<0.05; CD20 + /CD38 + : t1-t7 and t8 vs t0, p<0.05. ND, normal donors; t0, baseline; t1-t7, time points of the immunological study after each course of chemotherapy; t8, time point at follow-up, one month after the last course of chemotherapy. + : t0 and t1-t7 vs ND, p<0.05. ND, normal donors; t0, baseline; t1-t7, time points of the immunological study after each course of chemotherapy; t8, time point at follow-up, one month after the last course of chemotherapy. Figure 3 . Mean percentages of dendritic cells (DCs) from normal donors and breast cancer patients at baseline, during chemotherapy and at follow-up. DC1: t0 vs ND, p=0.01; DC2: t0 vs ND, p=0.02; t1-t7 vs t0, p=0.01. DC1/DC2: t1-t7 vs t0, p=0.002. ND, normal donors; t0, baseline; t1-t7, time points of the immunological study after each course of chemotherapy; t8, time point at follow-up, one month after the last course of chemotherapy.
HLA-DR-positive and CD3-, CD19-, CD20-, CD11b-, CD56-, CD16-, CD34-and CD14-FITC-negative. At least 2 peripheral blood DC subsets were described: myeloid-derived CD11c Statistics. Statistical comparisons between absolute lymphocyte counts and subsets in patients and healthy controls were performed by the t-test for independent samples, while comparisons versus baseline values were carried out by the t-test for paired observations.
Results
Breast cancer patients undergoing dose-dense CT followed by peg-filgrastim showed a significant increase in overall leukocyte number from the first CT course as compared to the baseline. Conversely, the total lymphocyte number tended to decrease with a negative peak following the 6th course of CT (p=0.03). B (CD19 + , CD20 + ) and early B lymphocyte subsets (CD20 + /CD38 + ) significantly decreased during the treatment period (p<0.05) (Fig. 1) . T lymphocyte subsets (CD2, CD3, CD8) did not show significant changes, with the exception of the T-helper subset (CD4 + ), which significantly decreased from the 4th CT course with a subsequent decrease in the CD4/CD8 ratio (p<0.05). The CD4 + /CD8 + subset, identifying immature T lymphocytes, increased compared to the baseline. With respect to the healthy controls, breast cancer patients showed a statistically significant increase in the number of natural killer (NK) cells (CD56 + ), which persisted throughout the treatment (Fig. 2) .
The absolute number of lymphocytes (ANL), T and B subsets were not significantly altered in breast cancer patients with respect to the healthy controls. During treatment, the percentage of the DC2 subset was further increased; the DC1/DC2 ratio consequently decreased. The mean percentage of DCs was not significantly altered in CT-naïve with respect to 20 normal donors (NDs) utilised as controls; the mean percentage of the DC subset was only significantly increased as compared to that of the NDs (Fig. 3) .
After 1 month of follow-up, circulating leukocyte, lymphocyte and DC mean values were normalised. A slight increase in the DC1 number, the DC1/DC2 ratio and the NK cell subset was observed, together with a decrease in CD4 + cells and the CD4/CD8 ratio, although without statistical significance. Only B lymphocytes showed a persistent significant decrease at 1 month of follow-up (p<0.05) (Fig. 1) . The median values of the absolute number of PBLs, lymphocytes and T, B and NK subsets are summarised in Table II .
Discussion
The impact of cytotoxic CT on the immune system has not as yet been fully elucidated. Mackall reported on the immunosuppressive effects of cytotoxic CT, such as a decrease in total T lymphocytes and the CD4 + subset following adjuvant CT and radiotherapy for breast cancer and the slow recovery of CD3 -/CD4 + lymphocytes in patients treated with intensive CT (2). Significant reductions in the absolute number of CD4 + lymphocytes were also reported by Sewell et al (9) in breast cancer patients treated with standard CT and by Sara et al (10) in patients with solid tumours treated with CT. Schroeder and colleagues (11) reported specific alterations of the T cell population in patients with breast cancer, such as a significant reduction in the absolute T cell number, but not in the CD4 + /CD8 + ratio and a significant increase in CD3 + T cells. In contrast with such aberrations of PBL reported in patients submitted to cytotoxic CT, Melichar et al (12) observed only a few distinct PBL changes in a population of breast cancer patients and suggested the presence of T-cell Table II . Absolute number of peripheral blood leukocytes, lymphocytes, T, B and NK subsets in normal donors and early breast cancer patients before, during and post dose-dense CT + peg-filgrastim treatment. 
ND, normal donors. t0, baseline; t1-t7, time points of the immunological study after each course of chemotherapy; t8, time point of followup one month after the last course of chemotherapy; WBC, white blood cells; ANL, absolute number of lymphocytes; NS, not significant.
activation. Our group previously found little impact of a topotecan-based CT on lymphocyte subsets of either naïve or pre-treated ovarian cancer patients (8) .
This study suggests that peg-filgrastim-supported dosedense adjuvant anthracycline-and taxane-based CT does not significantly affect the immune system of breast cancer patients. In particular, T lymphocyte subsets did not show significant changes, except for a decrease in the number of T helper (CD4 + ) cells. Following the discontinuation of CT, the mean values of leukocytes, total lymphocytes and NK subsets tended to return to baseline values. The substantial preservation of NK and DCs during cytotoxic therapy and follow-up seems to indicate a preservation of the immune competence by these regimens of adjuvant CT. Only B (CD19 + , CD20 + ) and early B (CD20 + /CD38 + ) lymphocytes decreased significantly over the entire CT period, and the decrease persisted at follow-up.
It must be noted that our CT regimens consisted of taxol and were supported by peg-filgrastim. Taxanes have been previously reported to exert immunostimulatory effects, which were hypothesised to be implicated in anti-tumour activity (13) . G-CSF itself was shown to have a number of effects on immune function. In preclinical studies, improvements in neutrophil count and antibacterial activity were reported, and also direct immunomodulatory properties were observed (6). Thus, taxol and peg-filgrastim might have played a role in the relatively small impact on the immune system observed in our cohort.
In conclusion, the outcome of our study regarding the changes in the PBL phenotype in a subset of breast cancer patients suggest that dose-dense CT programs with pegfilgrastim support do not significantly affect the immune system and allow for a rapid restoration of most immune competent cells. These findings may have important clinical implications for the improvement of immunotherapeutic approaches to cancer.
